BioNTech to Hold Press Conference to Provide an Update on COVID-19 Vaccine Development Program
Mainz, Germany, December 02, 2020 (GLOBE NEWSWIRE) – (Nasdaq: BNTX, “BioNTech” or “the Company”) will hold a press conference including a video webcast on Wednesday, December 2, 2020, to provide an update on the status of the COVID-19 vaccine development program of its lead vaccine candidate BNT162b2. The event will be held in English:
International press conference at 12.30pm CET / 6.30am ET
Please register .
Interested journalists may dial in 10-15 minutes before the conference starts. They will be able to submit questions via an online tool.
Participants may also access the press conference, including the video webcast, on under "Events & Presentations" in the Investor & Media section of the website. A recording of the press conference will be available on the same day. Additional media materials including images and videos can be accessed through the following link: .
About BioNTech
Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer.
For more information, please visit .
BioNTech Contacts
Media Relations
Jasmina Alatovic
Director External Communications
+49 (0)6131 9084 1513 or +49 (0)89 62 81 75 46
Investor Relations
Sylke Maas, Ph.D.
VP Investor Relations & Business Strategy
+49 (0)6131 9084 1074
